Novotech Recognised for Data-Driven Innovation and Global CRO Expansion

• Novotech received awards in Business Expansion, Innovation, and Marketing from the 2024 Clinical Trials Arena Excellence Awards.

• CEO Dr. John Moller and Global Marketing Director Toyna Chin expressed pride in the team’s accomplishments.

Novotech, a global clinical Contract Research Organization (CRO), has been honoured with multiple awards in the 2024 Clinical Trials Arena Excellence Awards. The awards recognise achievements in Business Expansion, Innovation, and Marketing, underlining the company’s strategic growth and technological advancements in the biotech sector.

Dr. John Moller, CEO of Novotech, praised the team’s dedication, stating, “We’re grateful for this recognition, which is a direct result of our team’s effort and commitment to our mission. It’s a reminder of what we can accomplish when we work together, and we look forward to continuing this momentum.”

The award for Business Expansion highlights Novotech’s recent acquisitions, including NCGS, EastHORN, and CBR International, which have enhanced its service portfolio and established a broader presence in biotech hubs. Additionally, the launch of the Early Phase Strategic Delivery Unit (EP SDU) allows Novotech to support early-stage trials by capitalising on the regulatory advantages in Australia and New Zealand.

In Innovation, Novotech’s use of AI and big data analytics has been instrumental in streamlining trial design and patient recruitment. Through partnerships with Medidata and ObvioHealth, Novotech has advanced its capabilities in virtual trials, enhancing both speed and efficiency in clinical development.

Novotech’s Marketing Leadership award acknowledges the work led by Toyna Chin, Global Director of Marketing, who oversaw a rebranding campaign that raised Novotech’s visibility in the US and European markets. Chin remarked, “This award is a tribute to the passion and unity that drives us forward, proving that true marketing excellence is always the result of a collective vision and shared purpose.”